Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dry Eye Syndromes | 135 | 2024 | 261 | 32.840 |
Why?
|
Tears | 96 | 2024 | 165 | 17.900 |
Why?
|
Conjunctiva | 88 | 2024 | 225 | 17.300 |
Why?
|
Epithelium, Corneal | 85 | 2024 | 176 | 13.960 |
Why?
|
Cornea | 94 | 2024 | 681 | 10.140 |
Why?
|
Goblet Cells | 33 | 2024 | 121 | 9.450 |
Why?
|
Sjogren's Syndrome | 34 | 2023 | 105 | 8.290 |
Why?
|
Keratoconjunctivitis Sicca | 25 | 2024 | 45 | 6.720 |
Why?
|
Lacrimal Apparatus | 43 | 2022 | 185 | 6.640 |
Why?
|
Eye | 19 | 2023 | 283 | 3.850 |
Why?
|
Conjunctival Diseases | 10 | 2023 | 35 | 3.780 |
Why?
|
Meibomian Glands | 19 | 2021 | 32 | 3.720 |
Why?
|
Cytokines | 47 | 2024 | 2826 | 3.470 |
Why?
|
Corneal Diseases | 20 | 2023 | 106 | 3.350 |
Why?
|
Interferon-gamma | 20 | 2024 | 1180 | 3.350 |
Why?
|
Ophthalmic Solutions | 30 | 2022 | 97 | 3.160 |
Why?
|
Mice, Inbred C57BL | 71 | 2024 | 7097 | 2.890 |
Why?
|
Disease Models, Animal | 53 | 2024 | 7383 | 2.810 |
Why?
|
Cyclosporine | 14 | 2020 | 292 | 2.390 |
Why?
|
Epithelial Cells | 38 | 2021 | 1875 | 2.260 |
Why?
|
Eyelid Diseases | 11 | 2015 | 75 | 2.170 |
Why?
|
Desiccation | 18 | 2024 | 45 | 2.120 |
Why?
|
Inflammation | 29 | 2023 | 2517 | 2.100 |
Why?
|
Keratoconjunctivitis | 8 | 2021 | 20 | 2.080 |
Why?
|
Contact Lenses | 9 | 2021 | 40 | 2.060 |
Why?
|
Interleukin-13 | 6 | 2024 | 130 | 2.010 |
Why?
|
Dendritic Cells | 14 | 2024 | 1110 | 2.000 |
Why?
|
Blinking | 6 | 2023 | 43 | 2.000 |
Why?
|
Mucins | 10 | 2024 | 289 | 1.950 |
Why?
|
Keratitis | 16 | 2021 | 125 | 1.940 |
Why?
|
Immunity, Innate | 13 | 2024 | 700 | 1.920 |
Why?
|
Matrix Metalloproteinase 9 | 19 | 2015 | 350 | 1.920 |
Why?
|
CD4-Positive T-Lymphocytes | 15 | 2020 | 1052 | 1.830 |
Why?
|
Eye Proteins | 13 | 2021 | 275 | 1.810 |
Why?
|
Diagnostic Techniques, Ophthalmological | 9 | 2014 | 98 | 1.770 |
Why?
|
Fluorescein | 21 | 2023 | 41 | 1.750 |
Why?
|
Lacrimal Apparatus Diseases | 10 | 2017 | 144 | 1.740 |
Why?
|
Visual Acuity | 38 | 2024 | 861 | 1.740 |
Why?
|
Anti-Inflammatory Agents | 16 | 2023 | 451 | 1.740 |
Why?
|
Autoimmune Diseases | 6 | 2024 | 436 | 1.710 |
Why?
|
Osmolar Concentration | 19 | 2021 | 206 | 1.700 |
Why?
|
Limbus Corneae | 17 | 2021 | 33 | 1.690 |
Why?
|
Immunosuppressive Agents | 15 | 2014 | 1429 | 1.650 |
Why?
|
Doxycycline | 12 | 2016 | 179 | 1.640 |
Why?
|
RNA, Messenger | 45 | 2024 | 6397 | 1.590 |
Why?
|
Eye Diseases | 10 | 2019 | 129 | 1.560 |
Why?
|
Mice | 103 | 2024 | 35586 | 1.560 |
Why?
|
Animals | 136 | 2024 | 62031 | 1.540 |
Why?
|
Fluorescent Antibody Technique, Indirect | 26 | 2018 | 183 | 1.530 |
Why?
|
Corneal Ulcer | 10 | 2019 | 59 | 1.500 |
Why?
|
Interleukin-1 | 14 | 2024 | 475 | 1.460 |
Why?
|
Mucin 5AC | 5 | 2020 | 74 | 1.450 |
Why?
|
Corneal Topography | 15 | 2018 | 193 | 1.450 |
Why?
|
Fluorophotometry | 19 | 2019 | 32 | 1.400 |
Why?
|
Lubricant Eye Drops | 4 | 2019 | 10 | 1.390 |
Why?
|
Blepharitis | 4 | 2015 | 9 | 1.390 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 33 | 2024 | 1525 | 1.390 |
Why?
|
Gene Expression Regulation | 24 | 2018 | 4134 | 1.350 |
Why?
|
Cells, Cultured | 49 | 2024 | 5697 | 1.350 |
Why?
|
Carnitine | 4 | 2015 | 88 | 1.340 |
Why?
|
Humans | 289 | 2024 | 270631 | 1.320 |
Why?
|
Erythritol | 3 | 2014 | 4 | 1.290 |
Why?
|
Immune Tolerance | 5 | 2020 | 427 | 1.270 |
Why?
|
Stress, Physiological | 14 | 2016 | 493 | 1.270 |
Why?
|
Tomography, Optical Coherence | 7 | 2021 | 547 | 1.250 |
Why?
|
Cell Count | 18 | 2021 | 512 | 1.240 |
Why?
|
Epidermal Growth Factor | 13 | 2012 | 439 | 1.210 |
Why?
|
Th1 Cells | 7 | 2019 | 259 | 1.210 |
Why?
|
Azithromycin | 3 | 2015 | 79 | 1.190 |
Why?
|
Microscopy, Confocal | 20 | 2024 | 659 | 1.190 |
Why?
|
Conjunctivitis, Allergic | 9 | 2020 | 15 | 1.180 |
Why?
|
Mice, Knockout | 37 | 2020 | 5729 | 1.170 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 33 | 2017 | 3603 | 1.170 |
Why?
|
Female | 171 | 2024 | 148865 | 1.130 |
Why?
|
Stem Cells | 18 | 2021 | 1217 | 1.120 |
Why?
|
Antigen-Presenting Cells | 4 | 2019 | 286 | 1.110 |
Why?
|
Botulinum Toxins, Type A | 2 | 2022 | 179 | 1.030 |
Why?
|
MAP Kinase Signaling System | 6 | 2008 | 885 | 1.020 |
Why?
|
Prostheses and Implants | 3 | 2012 | 294 | 0.990 |
Why?
|
Aging | 13 | 2020 | 1550 | 0.980 |
Why?
|
Nerve Growth Factor | 2 | 2019 | 42 | 0.970 |
Why?
|
Real-Time Polymerase Chain Reaction | 19 | 2024 | 1199 | 0.960 |
Why?
|
Betaine | 2 | 2014 | 25 | 0.960 |
Why?
|
Eye Infections, Fungal | 7 | 2018 | 79 | 0.960 |
Why?
|
Apoptosis | 12 | 2022 | 7752 | 0.930 |
Why?
|
RNA | 10 | 2017 | 1064 | 0.920 |
Why?
|
Tumor Necrosis Factor-alpha | 16 | 2022 | 1585 | 0.910 |
Why?
|
Protein Precursors | 12 | 2017 | 249 | 0.910 |
Why?
|
Osmotic Pressure | 6 | 2024 | 44 | 0.910 |
Why?
|
Th2 Cells | 8 | 2019 | 252 | 0.910 |
Why?
|
Middle Aged | 117 | 2022 | 90294 | 0.900 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 6 | 2008 | 303 | 0.880 |
Why?
|
Trigeminal Nerve Diseases | 2 | 2021 | 14 | 0.880 |
Why?
|
Burns, Chemical | 6 | 2023 | 32 | 0.870 |
Why?
|
Keratomileusis, Laser In Situ | 6 | 2010 | 147 | 0.860 |
Why?
|
Adult | 108 | 2021 | 81946 | 0.860 |
Why?
|
Male | 130 | 2024 | 128316 | 0.860 |
Why?
|
Saline Solution, Hypertonic | 3 | 2008 | 26 | 0.850 |
Why?
|
Lacerations | 1 | 2023 | 35 | 0.840 |
Why?
|
Conjunctivitis | 3 | 2015 | 29 | 0.840 |
Why?
|
Keratoconus | 5 | 2011 | 60 | 0.830 |
Why?
|
Epithelium | 20 | 2011 | 781 | 0.820 |
Why?
|
Eye Infections, Bacterial | 14 | 2017 | 96 | 0.820 |
Why?
|
Transforming Growth Factor beta | 10 | 2013 | 1109 | 0.820 |
Why?
|
Blepharospasm | 1 | 2022 | 49 | 0.820 |
Why?
|
T-Lymphocytes | 12 | 2023 | 3943 | 0.810 |
Why?
|
Transcriptome | 4 | 2021 | 1954 | 0.810 |
Why?
|
Calcineurin Inhibitors | 2 | 2020 | 67 | 0.810 |
Why?
|
Orbital Neoplasms | 1 | 2024 | 233 | 0.800 |
Why?
|
Administration, Topical | 15 | 2015 | 258 | 0.800 |
Why?
|
Aged | 88 | 2024 | 73338 | 0.790 |
Why?
|
Dermatitis, Atopic | 3 | 2020 | 41 | 0.780 |
Why?
|
Blotting, Western | 21 | 2016 | 3586 | 0.770 |
Why?
|
Endophthalmitis | 17 | 2000 | 82 | 0.770 |
Why?
|
Signal Transduction | 27 | 2022 | 12098 | 0.760 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2024 | 331 | 0.750 |
Why?
|
Matrix Metalloproteinases | 5 | 2017 | 138 | 0.750 |
Why?
|
Interleukin-12 | 3 | 2018 | 267 | 0.740 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor | 4 | 2010 | 41 | 0.740 |
Why?
|
Transforming Growth Factor beta2 | 3 | 2010 | 27 | 0.740 |
Why?
|
Receptors, Nicotinic | 1 | 2022 | 205 | 0.740 |
Why?
|
Interleukin-17 | 8 | 2016 | 256 | 0.730 |
Why?
|
Glucocorticoids | 7 | 2016 | 618 | 0.730 |
Why?
|
Monocytes | 2 | 2022 | 790 | 0.730 |
Why?
|
Rosacea | 6 | 2001 | 15 | 0.720 |
Why?
|
Wound Healing | 10 | 2019 | 764 | 0.710 |
Why?
|
Retinoids | 1 | 2021 | 149 | 0.710 |
Why?
|
Autoantigens | 3 | 2012 | 248 | 0.710 |
Why?
|
Cell Differentiation | 16 | 2021 | 4117 | 0.710 |
Why?
|
Macrophages | 5 | 2024 | 1351 | 0.700 |
Why?
|
Vision Disorders | 6 | 2020 | 240 | 0.700 |
Why?
|
B7-2 Antigen | 2 | 2019 | 53 | 0.680 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 7 | 2018 | 105 | 0.680 |
Why?
|
Herpes Zoster Ophthalmicus | 4 | 2024 | 13 | 0.680 |
Why?
|
Tretinoin | 2 | 2021 | 618 | 0.670 |
Why?
|
Toll-Like Receptors | 6 | 2014 | 170 | 0.670 |
Why?
|
Anti-Bacterial Agents | 21 | 2017 | 3176 | 0.670 |
Why?
|
Prosthesis Implantation | 2 | 2012 | 242 | 0.670 |
Why?
|
Astigmatism | 7 | 2011 | 178 | 0.660 |
Why?
|
Transforming Growth Factor beta1 | 8 | 2015 | 294 | 0.660 |
Why?
|
Dexamethasone | 6 | 2016 | 1507 | 0.650 |
Why?
|
Case-Control Studies | 15 | 2021 | 6238 | 0.640 |
Why?
|
Th17 Cells | 7 | 2019 | 163 | 0.640 |
Why?
|
Aged, 80 and over | 44 | 2022 | 30994 | 0.640 |
Why?
|
Interferon Type I | 2 | 2020 | 282 | 0.640 |
Why?
|
Adoptive Transfer | 12 | 2020 | 431 | 0.630 |
Why?
|
Candida parapsilosis | 1 | 2018 | 3 | 0.620 |
Why?
|
Bone Marrow Cells | 4 | 2018 | 968 | 0.610 |
Why?
|
Membrane Proteins | 12 | 2017 | 2929 | 0.610 |
Why?
|
Inflammation Mediators | 7 | 2020 | 403 | 0.610 |
Why?
|
Matrix Metalloproteinase Inhibitors | 4 | 2016 | 58 | 0.600 |
Why?
|
Methylprednisolone | 4 | 2006 | 198 | 0.600 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 2 | 2016 | 73 | 0.590 |
Why?
|
Anterior Eye Segment | 2 | 2017 | 34 | 0.580 |
Why?
|
Interleukin-1beta | 6 | 2023 | 295 | 0.580 |
Why?
|
Corneal Opacity | 2 | 2024 | 23 | 0.580 |
Why?
|
Eye Burns | 5 | 2017 | 14 | 0.570 |
Why?
|
Candidiasis | 4 | 2018 | 278 | 0.570 |
Why?
|
Cell Degranulation | 1 | 2017 | 47 | 0.570 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2016 | 227 | 0.560 |
Why?
|
Prospective Studies | 24 | 2022 | 13412 | 0.560 |
Why?
|
Microbiota | 4 | 2019 | 548 | 0.550 |
Why?
|
Surveys and Questionnaires | 11 | 2021 | 5914 | 0.550 |
Why?
|
Glycoproteins | 1 | 2020 | 779 | 0.540 |
Why?
|
Autoimmunity | 5 | 2017 | 267 | 0.540 |
Why?
|
Homeostasis | 4 | 2021 | 926 | 0.520 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2010 | 219 | 0.520 |
Why?
|
Mitogen-Activated Protein Kinase 9 | 3 | 2011 | 32 | 0.520 |
Why?
|
Dacryocystitis | 5 | 2018 | 22 | 0.520 |
Why?
|
Receptor, ErbB-3 | 3 | 2001 | 126 | 0.520 |
Why?
|
Biomarkers | 24 | 2020 | 5060 | 0.520 |
Why?
|
Unfolded Protein Response | 1 | 2016 | 112 | 0.510 |
Why?
|
Disease Management | 4 | 2020 | 1089 | 0.510 |
Why?
|
Electric Stimulation Therapy | 1 | 2017 | 134 | 0.510 |
Why?
|
Mouth Mucosa | 1 | 2016 | 224 | 0.500 |
Why?
|
Herpesvirus 4, Human | 11 | 1994 | 960 | 0.500 |
Why?
|
Environment, Controlled | 1 | 2015 | 22 | 0.500 |
Why?
|
Cornified Envelope Proline-Rich Proteins | 7 | 2011 | 27 | 0.500 |
Why?
|
Severity of Illness Index | 10 | 2018 | 4374 | 0.490 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2024 | 2479 | 0.490 |
Why?
|
Ophthalmic Nerve | 3 | 2018 | 9 | 0.490 |
Why?
|
Permeability | 7 | 2018 | 160 | 0.490 |
Why?
|
Cholinergic Antagonists | 3 | 2013 | 61 | 0.480 |
Why?
|
Transglutaminases | 4 | 2008 | 99 | 0.480 |
Why?
|
ATP-Binding Cassette Transporters | 6 | 2008 | 317 | 0.480 |
Why?
|
Eye Infections, Viral | 6 | 2024 | 29 | 0.470 |
Why?
|
Gene Expression | 9 | 2016 | 3641 | 0.470 |
Why?
|
Protective Agents | 1 | 2014 | 51 | 0.460 |
Why?
|
Receptors, CXCR3 | 2 | 2013 | 35 | 0.460 |
Why?
|
Cell Membrane Permeability | 4 | 2012 | 123 | 0.440 |
Why?
|
Chemokines | 4 | 2010 | 290 | 0.440 |
Why?
|
Cell Survival | 8 | 2024 | 3062 | 0.430 |
Why?
|
Inflammasomes | 3 | 2023 | 174 | 0.430 |
Why?
|
Immunoenzyme Techniques | 12 | 2010 | 1189 | 0.430 |
Why?
|
Chemokine CXCL11 | 3 | 2018 | 9 | 0.420 |
Why?
|
Chemokine CXCL9 | 3 | 2018 | 24 | 0.420 |
Why?
|
Tissue Kallikreins | 1 | 2012 | 9 | 0.410 |
Why?
|
Herpesviridae Infections | 6 | 1994 | 181 | 0.410 |
Why?
|
Cranial Nerve Diseases | 2 | 2018 | 77 | 0.410 |
Why?
|
Scleritis | 5 | 2004 | 11 | 0.400 |
Why?
|
Sclera | 6 | 2021 | 62 | 0.400 |
Why?
|
Chemokine CXCL10 | 3 | 2016 | 106 | 0.400 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2016 | 714 | 0.390 |
Why?
|
Matrix Metalloproteinase 3 | 7 | 2014 | 25 | 0.390 |
Why?
|
Eyelids | 4 | 2012 | 156 | 0.390 |
Why?
|
Keratoplasty, Penetrating | 10 | 2024 | 54 | 0.390 |
Why?
|
Sensation | 5 | 2009 | 75 | 0.390 |
Why?
|
Mice, Inbred BALB C | 11 | 2020 | 2456 | 0.380 |
Why?
|
Receptors, Chemokine | 2 | 2011 | 113 | 0.380 |
Why?
|
Neuromuscular Agents | 1 | 2012 | 77 | 0.380 |
Why?
|
Cataract | 1 | 2013 | 236 | 0.380 |
Why?
|
In Situ Nick-End Labeling | 5 | 2011 | 438 | 0.370 |
Why?
|
Artificial Organs | 1 | 2010 | 14 | 0.370 |
Why?
|
Interleukin-1 Receptor-Like 1 Protein | 4 | 2020 | 28 | 0.370 |
Why?
|
Interleukin-33 | 4 | 2020 | 19 | 0.370 |
Why?
|
Cell Size | 2 | 2008 | 140 | 0.370 |
Why?
|
Corneal Wavefront Aberration | 1 | 2011 | 21 | 0.370 |
Why?
|
Plasma | 2 | 2022 | 146 | 0.370 |
Why?
|
Eye Injuries | 4 | 2006 | 51 | 0.360 |
Why?
|
Zymosan | 1 | 2010 | 11 | 0.360 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor Receptors | 3 | 2010 | 19 | 0.360 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2023 | 125 | 0.360 |
Why?
|
Cell Proliferation | 12 | 2024 | 7235 | 0.360 |
Why?
|
Paresthesia | 1 | 2010 | 33 | 0.360 |
Why?
|
Anti-Allergic Agents | 2 | 2014 | 26 | 0.360 |
Why?
|
Dehydration | 2 | 2007 | 91 | 0.350 |
Why?
|
Flow Cytometry | 10 | 2015 | 3044 | 0.350 |
Why?
|
Lymphocyte Activation | 8 | 2019 | 1723 | 0.350 |
Why?
|
Protein Kinase C-alpha | 1 | 2010 | 67 | 0.350 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2018 | 852 | 0.350 |
Why?
|
Intestinal Mucosa | 1 | 2016 | 1105 | 0.350 |
Why?
|
Autoantibodies | 3 | 2012 | 602 | 0.340 |
Why?
|
Vitrectomy | 7 | 2006 | 110 | 0.340 |
Why?
|
Lipopolysaccharides | 6 | 2019 | 588 | 0.340 |
Why?
|
Corneal Transplantation | 7 | 2013 | 51 | 0.340 |
Why?
|
Butyrates | 2 | 2022 | 56 | 0.340 |
Why?
|
Staining and Labeling | 6 | 2013 | 445 | 0.340 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2007 | 669 | 0.340 |
Why?
|
Polyendocrinopathies, Autoimmune | 1 | 2009 | 9 | 0.340 |
Why?
|
Androstadienes | 2 | 2014 | 172 | 0.330 |
Why?
|
Interleukin-18 | 2 | 2023 | 91 | 0.330 |
Why?
|
Toll-Like Receptor 4 | 3 | 2016 | 210 | 0.330 |
Why?
|
Antigens, Plant | 3 | 2019 | 34 | 0.330 |
Why?
|
Imidazoles | 5 | 2015 | 1064 | 0.330 |
Why?
|
Postoperative Complications | 10 | 2014 | 5672 | 0.330 |
Why?
|
Nerve Regeneration | 1 | 2009 | 118 | 0.330 |
Why?
|
T-Lymphocyte Subsets | 3 | 2019 | 593 | 0.320 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2020 | 241 | 0.320 |
Why?
|
Lissamine Green Dyes | 4 | 2013 | 7 | 0.320 |
Why?
|
Contact Lens Solutions | 1 | 2008 | 5 | 0.320 |
Why?
|
Receptors, Interleukin-1 Type I | 1 | 2008 | 15 | 0.320 |
Why?
|
Biomedical Engineering | 1 | 2008 | 40 | 0.320 |
Why?
|
Myopia | 3 | 2006 | 196 | 0.320 |
Why?
|
Killer Cells, Natural | 2 | 2012 | 965 | 0.320 |
Why?
|
GTP-Binding Proteins | 2 | 2008 | 342 | 0.320 |
Why?
|
NF-kappa B | 10 | 2023 | 1564 | 0.310 |
Why?
|
Fluorescent Antibody Technique | 10 | 2018 | 1121 | 0.310 |
Why?
|
Interleukins | 5 | 2021 | 341 | 0.310 |
Why?
|
Cautery | 2 | 2023 | 9 | 0.310 |
Why?
|
Disability Evaluation | 1 | 2010 | 237 | 0.310 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2022 | 659 | 0.310 |
Why?
|
Isotonic Solutions | 1 | 2008 | 41 | 0.310 |
Why?
|
Young Adult | 21 | 2020 | 22201 | 0.310 |
Why?
|
Caspases | 5 | 2011 | 679 | 0.310 |
Why?
|
Sodium | 2 | 2010 | 323 | 0.310 |
Why?
|
Ophthalmology | 4 | 2018 | 204 | 0.310 |
Why?
|
Primary Cell Culture | 4 | 2018 | 200 | 0.310 |
Why?
|
Phenylalanine | 3 | 2018 | 166 | 0.310 |
Why?
|
Nasolacrimal Duct | 3 | 2017 | 45 | 0.310 |
Why?
|
Immunohistochemistry | 15 | 2019 | 7663 | 0.310 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p57 | 2 | 2012 | 61 | 0.300 |
Why?
|
Recombinant Proteins | 7 | 2019 | 3027 | 0.300 |
Why?
|
Immunity, Mucosal | 3 | 2014 | 121 | 0.300 |
Why?
|
Amino Acids, Diamino | 2 | 2024 | 2 | 0.300 |
Why?
|
Receptor, trkA | 1 | 2007 | 40 | 0.290 |
Why?
|
Nerve Growth Factors | 2 | 2007 | 128 | 0.290 |
Why?
|
Cytochromes c | 1 | 2007 | 117 | 0.290 |
Why?
|
Dibenzoxepins | 1 | 2006 | 1 | 0.290 |
Why?
|
Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 4 | 0.290 |
Why?
|
Dibenzazepines | 1 | 2006 | 3 | 0.280 |
Why?
|
Disease Susceptibility | 2 | 2020 | 550 | 0.280 |
Why?
|
Histamine H1 Antagonists | 1 | 2006 | 25 | 0.280 |
Why?
|
Intermediate Filament Proteins | 2 | 2006 | 80 | 0.280 |
Why?
|
Proto-Oncogene Proteins c-ets | 2 | 2018 | 96 | 0.280 |
Why?
|
Oxidative Stress | 5 | 2017 | 1149 | 0.280 |
Why?
|
Stress, Mechanical | 2 | 2007 | 273 | 0.280 |
Why?
|
Immunoglobulin G | 4 | 2012 | 1129 | 0.280 |
Why?
|
Vitreous Body | 8 | 1995 | 116 | 0.280 |
Why?
|
Sialoglycoproteins | 3 | 2001 | 151 | 0.280 |
Why?
|
Drug Therapy, Combination | 9 | 2014 | 2344 | 0.280 |
Why?
|
Lactoferrin | 5 | 2001 | 87 | 0.280 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2006 | 79 | 0.280 |
Why?
|
Dysbiosis | 2 | 2019 | 153 | 0.280 |
Why?
|
Administration, Intranasal | 2 | 2017 | 180 | 0.270 |
Why?
|
Xerophthalmia | 3 | 2014 | 8 | 0.270 |
Why?
|
Gene Expression Regulation, Enzymologic | 3 | 2016 | 695 | 0.270 |
Why?
|
Serum | 1 | 2006 | 71 | 0.270 |
Why?
|
Cell Communication | 2 | 2020 | 512 | 0.270 |
Why?
|
Receptor, ErbB-2 | 3 | 2001 | 2651 | 0.260 |
Why?
|
Phenotype | 12 | 2019 | 6504 | 0.260 |
Why?
|
Plant Extracts | 2 | 2019 | 225 | 0.260 |
Why?
|
Stevens-Johnson Syndrome | 2 | 2016 | 19 | 0.260 |
Why?
|
Chemokine CCL5 | 2 | 2021 | 76 | 0.260 |
Why?
|
Treatment Outcome | 19 | 2021 | 33722 | 0.260 |
Why?
|
Occludin | 4 | 2011 | 26 | 0.250 |
Why?
|
Corneal Neovascularization | 2 | 2023 | 13 | 0.250 |
Why?
|
Aqueous Humor | 4 | 1999 | 31 | 0.250 |
Why?
|
Retrospective Studies | 28 | 2021 | 39811 | 0.250 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 1 | 2004 | 3 | 0.250 |
Why?
|
Peptide Fragments | 3 | 2011 | 1309 | 0.240 |
Why?
|
Diabetic Retinopathy | 2 | 2006 | 153 | 0.240 |
Why?
|
Organ Size | 2 | 2021 | 692 | 0.240 |
Why?
|
ErbB Receptors | 4 | 2006 | 2376 | 0.240 |
Why?
|
Phagocytes | 1 | 2024 | 47 | 0.240 |
Why?
|
Ulcer | 2 | 2004 | 80 | 0.240 |
Why?
|
Collagenases | 3 | 2004 | 74 | 0.240 |
Why?
|
Collagen Type IV | 1 | 2005 | 107 | 0.240 |
Why?
|
Prevalence | 4 | 2023 | 3401 | 0.240 |
Why?
|
Cross-Over Studies | 2 | 2017 | 452 | 0.240 |
Why?
|
Interleukin-8 | 3 | 2020 | 531 | 0.230 |
Why?
|
Autophagy | 2 | 2020 | 910 | 0.230 |
Why?
|
Caspase 3 | 4 | 2007 | 474 | 0.230 |
Why?
|
Transcription Factors | 6 | 2015 | 5439 | 0.230 |
Why?
|
Hyperesthesia | 1 | 2004 | 4 | 0.230 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2005 | 470 | 0.230 |
Why?
|
Fluorescent Dyes | 5 | 2012 | 469 | 0.230 |
Why?
|
Antifungal Agents | 5 | 2018 | 880 | 0.230 |
Why?
|
Forkhead Transcription Factors | 5 | 2020 | 763 | 0.230 |
Why?
|
Mucous Membrane | 4 | 2013 | 263 | 0.230 |
Why?
|
Candida albicans | 3 | 2015 | 186 | 0.230 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 3844 | 0.230 |
Why?
|
Air | 1 | 2004 | 65 | 0.230 |
Why?
|
Adaptive Immunity | 2 | 2017 | 151 | 0.230 |
Why?
|
Reactive Oxygen Species | 4 | 2017 | 1006 | 0.220 |
Why?
|
Enzyme Activation | 4 | 2014 | 1811 | 0.220 |
Why?
|
Contact Lenses, Extended-Wear | 3 | 2000 | 5 | 0.220 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2004 | 65 | 0.220 |
Why?
|
Homeodomain Proteins | 4 | 2018 | 1124 | 0.220 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2004 | 207 | 0.220 |
Why?
|
Polymerase Chain Reaction | 8 | 2015 | 3478 | 0.220 |
Why?
|
Gastrointestinal Microbiome | 3 | 2022 | 982 | 0.220 |
Why?
|
Specimen Handling | 2 | 1997 | 306 | 0.210 |
Why?
|
Interferometry | 1 | 2022 | 26 | 0.210 |
Why?
|
HLA-DR Antigens | 5 | 2015 | 184 | 0.210 |
Why?
|
Metalloendopeptidases | 1 | 2003 | 176 | 0.210 |
Why?
|
Hormones | 1 | 2004 | 285 | 0.210 |
Why?
|
Organic Chemicals | 4 | 2015 | 104 | 0.210 |
Why?
|
Antirheumatic Agents | 1 | 2005 | 230 | 0.200 |
Why?
|
Genes, Regulator | 1 | 2022 | 81 | 0.200 |
Why?
|
Sulfones | 3 | 2018 | 145 | 0.200 |
Why?
|
Follow-Up Studies | 14 | 2019 | 15204 | 0.200 |
Why?
|
Cell Movement | 6 | 2016 | 2471 | 0.200 |
Why?
|
Histamine | 1 | 2022 | 60 | 0.200 |
Why?
|
Immunophenotyping | 4 | 2018 | 1726 | 0.200 |
Why?
|
Lasers | 1 | 2023 | 235 | 0.200 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 4 | 2008 | 344 | 0.200 |
Why?
|
Nociceptors | 1 | 2022 | 94 | 0.200 |
Why?
|
Double-Blind Method | 5 | 2019 | 2588 | 0.200 |
Why?
|
Mice, Inbred NOD | 3 | 2016 | 897 | 0.200 |
Why?
|
Corneal Dystrophies, Hereditary | 1 | 2021 | 10 | 0.200 |
Why?
|
Prednisolone | 2 | 2001 | 133 | 0.200 |
Why?
|
Fourier Analysis | 2 | 2012 | 91 | 0.200 |
Why?
|
Hyaluronic Acid | 2 | 2017 | 152 | 0.190 |
Why?
|
Hypesthesia | 1 | 2001 | 22 | 0.190 |
Why?
|
Arthritis, Rheumatoid | 2 | 2005 | 496 | 0.190 |
Why?
|
Matrix Metalloproteinase 8 | 2 | 2016 | 16 | 0.190 |
Why?
|
Germ-Free Life | 2 | 2018 | 67 | 0.190 |
Why?
|
Interleukin-12 Subunit p35 | 1 | 2021 | 10 | 0.190 |
Why?
|
Vitamin A Deficiency | 1 | 2021 | 22 | 0.190 |
Why?
|
Autophagy-Related Protein-1 Homolog | 1 | 2020 | 12 | 0.190 |
Why?
|
Emulsions | 4 | 2010 | 86 | 0.190 |
Why?
|
Reproducibility of Results | 9 | 2023 | 6191 | 0.190 |
Why?
|
Matrix Metalloproteinase 1 | 3 | 2009 | 51 | 0.190 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2021 | 160 | 0.190 |
Why?
|
Pterygium | 1 | 2000 | 5 | 0.180 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 676 | 0.180 |
Why?
|
Bromodeoxyuridine | 4 | 2010 | 129 | 0.180 |
Why?
|
Biomedical Research | 2 | 2018 | 798 | 0.180 |
Why?
|
Receptors, Interleukin-9 | 1 | 2020 | 3 | 0.180 |
Why?
|
Trehalose | 1 | 2020 | 25 | 0.180 |
Why?
|
Contrast Sensitivity | 1 | 2000 | 66 | 0.180 |
Why?
|
Vitamin A | 1 | 2021 | 91 | 0.180 |
Why?
|
Sickness Impact Profile | 2 | 2013 | 138 | 0.180 |
Why?
|
Cytoprotection | 4 | 2020 | 64 | 0.180 |
Why?
|
Uveitis | 1 | 2020 | 39 | 0.180 |
Why?
|
Infectious Mononucleosis | 2 | 1993 | 38 | 0.180 |
Why?
|
Humidity | 3 | 2015 | 28 | 0.180 |
Why?
|
Matrix Metalloproteinase 13 | 2 | 2014 | 22 | 0.180 |
Why?
|
Interleukin-9 | 1 | 2020 | 37 | 0.180 |
Why?
|
Reflex | 2 | 2017 | 70 | 0.180 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 557 | 0.180 |
Why?
|
Carbachol | 2 | 1996 | 33 | 0.180 |
Why?
|
Sensitivity and Specificity | 7 | 2011 | 5171 | 0.170 |
Why?
|
Metaplasia | 3 | 2009 | 384 | 0.170 |
Why?
|
Cell Line | 6 | 2010 | 5339 | 0.170 |
Why?
|
DNA Primers | 6 | 2013 | 1496 | 0.170 |
Why?
|
Cell Division | 5 | 2010 | 2657 | 0.170 |
Why?
|
Trigeminal Nerve | 2 | 1997 | 17 | 0.170 |
Why?
|
Cell Adhesion Molecules | 2 | 2015 | 572 | 0.170 |
Why?
|
Administration, Ophthalmic | 1 | 2019 | 6 | 0.170 |
Why?
|
Curcumin | 1 | 2020 | 119 | 0.170 |
Why?
|
Carrier Proteins | 3 | 2015 | 2099 | 0.170 |
Why?
|
Alkalies | 5 | 2017 | 29 | 0.170 |
Why?
|
Receptors, Retinoic Acid | 1 | 2021 | 369 | 0.170 |
Why?
|
Methylprednisolone Hemisuccinate | 1 | 1999 | 18 | 0.170 |
Why?
|
ROC Curve | 1 | 2023 | 1249 | 0.170 |
Why?
|
Flagellin | 3 | 2014 | 23 | 0.170 |
Why?
|
Mycoses | 2 | 1997 | 393 | 0.170 |
Why?
|
Myeloid Cells | 1 | 2021 | 273 | 0.170 |
Why?
|
Preservatives, Pharmaceutical | 1 | 1999 | 14 | 0.170 |
Why?
|
Keratitis, Dendritic | 4 | 1992 | 18 | 0.160 |
Why?
|
Drug Delivery Systems | 4 | 2016 | 661 | 0.160 |
Why?
|
Biopsy | 3 | 2024 | 3482 | 0.160 |
Why?
|
Interleukin-27 | 1 | 2019 | 7 | 0.160 |
Why?
|
Refraction, Ocular | 2 | 2018 | 300 | 0.160 |
Why?
|
Macrophage Activation | 1 | 2019 | 151 | 0.160 |
Why?
|
Ophthalmologic Surgical Procedures | 3 | 2018 | 141 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 2 | 2009 | 44 | 0.160 |
Why?
|
Mice, Transgenic | 3 | 2018 | 4223 | 0.160 |
Why?
|
OX40 Ligand | 3 | 2019 | 23 | 0.160 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2015 | 678 | 0.160 |
Why?
|
Lens Capsule, Crystalline | 2 | 2017 | 51 | 0.160 |
Why?
|
Lymphocytes | 3 | 2022 | 1275 | 0.160 |
Why?
|
Chromans | 1 | 2018 | 28 | 0.160 |
Why?
|
Fluoresceins | 4 | 2002 | 74 | 0.160 |
Why?
|
Polysaccharides, Bacterial | 4 | 2014 | 72 | 0.160 |
Why?
|
Practice Guidelines as Topic | 3 | 2015 | 2394 | 0.160 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2014 | 258 | 0.160 |
Why?
|
Antibodies, Monoclonal | 8 | 2020 | 4480 | 0.160 |
Why?
|
Antibodies | 3 | 2017 | 809 | 0.160 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 190 | 0.160 |
Why?
|
RNA, Small Interfering | 4 | 2012 | 2196 | 0.150 |
Why?
|
Enzyme Inhibitors | 4 | 2007 | 1946 | 0.150 |
Why?
|
Models, Biological | 4 | 2020 | 3194 | 0.150 |
Why?
|
Adolescent | 20 | 2024 | 32719 | 0.150 |
Why?
|
Adrenal Cortex Hormones | 3 | 2013 | 565 | 0.150 |
Why?
|
Caspase 1 | 3 | 2017 | 62 | 0.150 |
Why?
|
Symbiosis | 1 | 2018 | 76 | 0.150 |
Why?
|
DNA, Mitochondrial | 2 | 2017 | 313 | 0.150 |
Why?
|
Pilot Projects | 3 | 2010 | 2846 | 0.150 |
Why?
|
Antibodies, Viral | 6 | 1995 | 1301 | 0.150 |
Why?
|
Biological Dressings | 2 | 2001 | 6 | 0.150 |
Why?
|
Sex | 1 | 1997 | 11 | 0.150 |
Why?
|
Injections, Subcutaneous | 2 | 2011 | 342 | 0.150 |
Why?
|
Transfection | 3 | 2008 | 3118 | 0.150 |
Why?
|
Benzoates | 1 | 2018 | 128 | 0.150 |
Why?
|
Growth Substances | 1 | 1998 | 326 | 0.150 |
Why?
|
Microscopy, Fluorescence | 2 | 2015 | 768 | 0.150 |
Why?
|
beta-Defensins | 2 | 2014 | 31 | 0.140 |
Why?
|
Hospitals, County | 1 | 2017 | 31 | 0.140 |
Why?
|
Ciliary Body | 1 | 2017 | 34 | 0.140 |
Why?
|
Receptors, Cytokine | 3 | 2019 | 179 | 0.140 |
Why?
|
Corneal Injuries | 1 | 2017 | 31 | 0.140 |
Why?
|
Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2017 | 30 | 0.140 |
Why?
|
Ultrasonics | 1 | 2017 | 65 | 0.140 |
Why?
|
Immune System | 2 | 2009 | 275 | 0.140 |
Why?
|
Cell Culture Techniques | 4 | 2017 | 574 | 0.140 |
Why?
|
Simplexvirus | 6 | 1995 | 180 | 0.140 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 2014 | 66 | 0.140 |
Why?
|
Hypersensitivity | 1 | 2019 | 220 | 0.140 |
Why?
|
DNA, Viral | 5 | 1997 | 756 | 0.140 |
Why?
|
Muscarinic Agonists | 1 | 1996 | 42 | 0.140 |
Why?
|
Itraconazole | 1 | 1997 | 81 | 0.140 |
Why?
|
Contrast Media | 2 | 2000 | 1498 | 0.140 |
Why?
|
Blotting, Northern | 4 | 2005 | 726 | 0.140 |
Why?
|
Cysteamine | 1 | 2016 | 14 | 0.140 |
Why?
|
Laser Coagulation | 1 | 2018 | 141 | 0.140 |
Why?
|
Cystinosis | 1 | 2016 | 15 | 0.140 |
Why?
|
Caspase 8 | 1 | 2017 | 146 | 0.140 |
Why?
|
Ovalbumin | 1 | 2017 | 390 | 0.140 |
Why?
|
Immunoblotting | 2 | 2016 | 895 | 0.140 |
Why?
|
Hospitals, High-Volume | 1 | 2017 | 76 | 0.140 |
Why?
|
Immunotherapy | 1 | 2010 | 3553 | 0.130 |
Why?
|
Blueberry Plants | 1 | 2016 | 5 | 0.130 |
Why?
|
Cell Separation | 3 | 2011 | 610 | 0.130 |
Why?
|
Transduction, Genetic | 2 | 2008 | 494 | 0.130 |
Why?
|
Connexin 43 | 4 | 2017 | 46 | 0.130 |
Why?
|
Tongue | 1 | 2016 | 85 | 0.130 |
Why?
|
Clusterin | 1 | 2015 | 28 | 0.130 |
Why?
|
Microscopy | 1 | 2017 | 189 | 0.130 |
Why?
|
Tissue Scaffolds | 1 | 2017 | 134 | 0.130 |
Why?
|
Antioxidants | 2 | 2016 | 522 | 0.130 |
Why?
|
Environmental Exposure | 2 | 2017 | 287 | 0.130 |
Why?
|
Integrin alpha Chains | 1 | 2015 | 23 | 0.130 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2015 | 20 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 5070 | 0.130 |
Why?
|
Tissue and Organ Procurement | 1 | 2018 | 238 | 0.130 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2024 | 2453 | 0.130 |
Why?
|
Nanoparticles | 1 | 2020 | 585 | 0.130 |
Why?
|
Toxoplasmosis, Ocular | 1 | 1995 | 2 | 0.130 |
Why?
|
Retinal Necrosis Syndrome, Acute | 1 | 1995 | 3 | 0.130 |
Why?
|
Neutralization Tests | 2 | 2011 | 286 | 0.120 |
Why?
|
Flavonoids | 2 | 2007 | 201 | 0.120 |
Why?
|
Reference Values | 4 | 1998 | 1134 | 0.120 |
Why?
|
Multiple Myeloma | 1 | 2007 | 2281 | 0.120 |
Why?
|
Corneal Stroma | 2 | 2012 | 93 | 0.120 |
Why?
|
Laser Therapy | 2 | 2018 | 466 | 0.120 |
Why?
|
Interleukin-6 | 3 | 2020 | 1051 | 0.120 |
Why?
|
Cell Adhesion | 4 | 2016 | 1028 | 0.120 |
Why?
|
Nasal Cavity | 1 | 1996 | 154 | 0.120 |
Why?
|
Adenovirus Infections, Human | 1 | 1995 | 55 | 0.120 |
Why?
|
Paclitaxel | 1 | 2022 | 2100 | 0.120 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2014 | 33 | 0.120 |
Why?
|
CD4 Antigens | 2 | 2020 | 170 | 0.120 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 56 | 0.120 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 1993 | 170 | 0.120 |
Why?
|
Pyridines | 3 | 2007 | 1311 | 0.120 |
Why?
|
Hot Temperature | 1 | 2015 | 289 | 0.120 |
Why?
|
Conjunctival Neoplasms | 1 | 1996 | 124 | 0.120 |
Why?
|
Cosmetic Techniques | 1 | 2014 | 23 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2020 | 1579 | 0.120 |
Why?
|
Photography | 2 | 1992 | 125 | 0.120 |
Why?
|
Analysis of Variance | 4 | 2014 | 2319 | 0.120 |
Why?
|
Autopsy | 1 | 2014 | 170 | 0.120 |
Why?
|
Nanotechnology | 1 | 2015 | 137 | 0.120 |
Why?
|
TRPV Cation Channels | 1 | 2014 | 75 | 0.120 |
Why?
|
Sodium Chloride | 1 | 2014 | 159 | 0.120 |
Why?
|
Histamine Antagonists | 1 | 2013 | 20 | 0.120 |
Why?
|
Recurrence | 6 | 2012 | 4875 | 0.110 |
Why?
|
Ultraviolet Rays | 2 | 2006 | 588 | 0.110 |
Why?
|
gamma-Linolenic Acid | 1 | 2013 | 3 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2015 | 416 | 0.110 |
Why?
|
Receptors, CCR6 | 1 | 2013 | 24 | 0.110 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 38 | 0.110 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 426 | 0.110 |
Why?
|
Biological Assay | 2 | 2010 | 178 | 0.110 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2012 | 202 | 0.110 |
Why?
|
Eye Protective Devices | 1 | 2013 | 9 | 0.110 |
Why?
|
Lens Implantation, Intraocular | 1 | 2017 | 340 | 0.110 |
Why?
|
Societies, Medical | 2 | 2018 | 1320 | 0.110 |
Why?
|
Mitomycin | 1 | 2014 | 213 | 0.110 |
Why?
|
Thrombospondin 1 | 1 | 2013 | 52 | 0.110 |
Why?
|
Observer Variation | 2 | 2010 | 709 | 0.110 |
Why?
|
Time Factors | 8 | 2020 | 13017 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 7 | 2017 | 1072 | 0.110 |
Why?
|
Phosphoproteins | 3 | 2008 | 1137 | 0.110 |
Why?
|
Models, Animal | 3 | 2017 | 656 | 0.110 |
Why?
|
Tetracycline | 2 | 2008 | 106 | 0.110 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2013 | 83 | 0.100 |
Why?
|
Feeder Cells | 1 | 2012 | 11 | 0.100 |
Why?
|
Up-Regulation | 5 | 2021 | 2421 | 0.100 |
Why?
|
Injections, Intraocular | 1 | 2012 | 10 | 0.100 |
Why?
|
Complement C3b | 1 | 2012 | 9 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2013 | 314 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 1996 | 489 | 0.100 |
Why?
|
Culture Media, Conditioned | 3 | 2017 | 255 | 0.100 |
Why?
|
Tumor Virus Infections | 1 | 1994 | 248 | 0.100 |
Why?
|
Refractive Errors | 1 | 2013 | 85 | 0.100 |
Why?
|
Feces | 1 | 2016 | 861 | 0.100 |
Why?
|
Refractive Surgical Procedures | 1 | 2013 | 73 | 0.100 |
Why?
|
Staphylococcus aureus | 2 | 1993 | 560 | 0.100 |
Why?
|
Corneal Edema | 1 | 1992 | 14 | 0.100 |
Why?
|
Keratin-12 | 2 | 2017 | 3 | 0.100 |
Why?
|
Coculture Techniques | 2 | 2012 | 628 | 0.100 |
Why?
|
Keratins | 3 | 2010 | 340 | 0.100 |
Why?
|
Neoplasm Proteins | 5 | 2007 | 3344 | 0.100 |
Why?
|
Genetic Vectors | 2 | 2008 | 1857 | 0.100 |
Why?
|
Complement Activation | 1 | 2012 | 93 | 0.100 |
Why?
|
Kallikreins | 1 | 2012 | 86 | 0.100 |
Why?
|
Eicosapentaenoic Acid | 1 | 2012 | 95 | 0.100 |
Why?
|
Surgical Instruments | 2 | 1992 | 141 | 0.100 |
Why?
|
Oculomotor Muscles | 1 | 2012 | 79 | 0.100 |
Why?
|
Receptors, Interferon | 1 | 2011 | 42 | 0.100 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2011 | 28 | 0.100 |
Why?
|
Immunity, Humoral | 1 | 2012 | 88 | 0.100 |
Why?
|
Immunization, Passive | 1 | 2012 | 188 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2014 | 1655 | 0.100 |
Why?
|
Antigens, Differentiation | 2 | 2011 | 247 | 0.100 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 2808 | 0.090 |
Why?
|
Prosthesis Fitting | 1 | 2011 | 14 | 0.090 |
Why?
|
Chemexfoliation | 1 | 1990 | 2 | 0.090 |
Why?
|
Prolapse | 1 | 2010 | 14 | 0.090 |
Why?
|
Immunomodulation | 1 | 2013 | 255 | 0.090 |
Why?
|
Wounds, Penetrating | 2 | 1988 | 157 | 0.090 |
Why?
|
Spectrometry, Fluorescence | 1 | 2011 | 206 | 0.090 |
Why?
|
Co-Repressor Proteins | 1 | 2011 | 120 | 0.090 |
Why?
|
Prodrugs | 1 | 2012 | 226 | 0.090 |
Why?
|
Receptors, Cholinergic | 1 | 2011 | 98 | 0.090 |
Why?
|
Staphylococcal Infections | 3 | 1993 | 679 | 0.090 |
Why?
|
Genes, Dominant | 1 | 2011 | 356 | 0.090 |
Why?
|
Loteprednol Etabonate | 2 | 2014 | 5 | 0.090 |
Why?
|
Chronic Disease | 3 | 2022 | 1825 | 0.090 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 2 | 2001 | 104 | 0.090 |
Why?
|
Mucin-4 | 2 | 2000 | 17 | 0.090 |
Why?
|
Mice, Nude | 3 | 2012 | 4329 | 0.090 |
Why?
|
STAT6 Transcription Factor | 1 | 2010 | 68 | 0.090 |
Why?
|
Nocardia Infections | 1 | 1990 | 35 | 0.090 |
Why?
|
Antigens, CD | 3 | 2012 | 1419 | 0.090 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2011 | 225 | 0.090 |
Why?
|
Antibodies, Neutralizing | 2 | 2013 | 518 | 0.090 |
Why?
|
beta Catenin | 2 | 2012 | 683 | 0.090 |
Why?
|
Tissue Engineering | 1 | 2012 | 255 | 0.090 |
Why?
|
Adult Stem Cells | 1 | 2011 | 69 | 0.090 |
Why?
|
Molecular Sequence Data | 7 | 2006 | 6686 | 0.090 |
Why?
|
fas Receptor | 1 | 2011 | 197 | 0.090 |
Why?
|
Coloring Agents | 1 | 2011 | 233 | 0.090 |
Why?
|
Lectins | 1 | 1990 | 148 | 0.090 |
Why?
|
Neutrophils | 2 | 2016 | 873 | 0.090 |
Why?
|
Trans-Activators | 3 | 2005 | 1624 | 0.090 |
Why?
|
Molecular Chaperones | 1 | 2011 | 266 | 0.090 |
Why?
|
False Positive Reactions | 1 | 2011 | 376 | 0.090 |
Why?
|
Dextrans | 1 | 2010 | 98 | 0.090 |
Why?
|
Photogrammetry | 1 | 1989 | 6 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2017 | 1280 | 0.090 |
Why?
|
Toll-Like Receptor 2 | 1 | 2010 | 95 | 0.090 |
Why?
|
Vancomycin | 3 | 1992 | 290 | 0.090 |
Why?
|
Biological Transport | 3 | 2012 | 627 | 0.090 |
Why?
|
Piperidines | 1 | 2015 | 1098 | 0.080 |
Why?
|
Transcription, Genetic | 1 | 1998 | 3341 | 0.080 |
Why?
|
Regeneration | 1 | 2012 | 283 | 0.080 |
Why?
|
Base Sequence | 6 | 2006 | 5437 | 0.080 |
Why?
|
Prognosis | 10 | 2017 | 22473 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2399 | 0.080 |
Why?
|
Nerve Fibers | 1 | 2009 | 120 | 0.080 |
Why?
|
Receptors, Cell Surface | 1 | 2013 | 904 | 0.080 |
Why?
|
Antigen Presentation | 1 | 2010 | 286 | 0.080 |
Why?
|
Acanthamoeba Keratitis | 2 | 2008 | 17 | 0.080 |
Why?
|
Streptococcal Infections | 1 | 1992 | 317 | 0.080 |
Why?
|
Capsid Proteins | 1 | 1990 | 219 | 0.080 |
Why?
|
Zonula Occludens-1 Protein | 1 | 2008 | 26 | 0.080 |
Why?
|
Defensins | 1 | 2008 | 12 | 0.080 |
Why?
|
Immunoassay | 1 | 2009 | 214 | 0.080 |
Why?
|
Phosphorylation | 2 | 2008 | 4945 | 0.080 |
Why?
|
Imaging, Three-Dimensional | 1 | 2013 | 908 | 0.080 |
Why?
|
Chemokine CCL3 | 1 | 2008 | 65 | 0.080 |
Why?
|
Hypertonic Solutions | 1 | 2008 | 27 | 0.080 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 3408 | 0.080 |
Why?
|
Economics, Pharmaceutical | 1 | 2008 | 16 | 0.080 |
Why?
|
Down-Regulation | 3 | 2012 | 2091 | 0.080 |
Why?
|
Swine | 2 | 2018 | 1607 | 0.080 |
Why?
|
AIDS-Related Complex | 1 | 1987 | 13 | 0.080 |
Why?
|
Receptor, Nerve Growth Factor | 1 | 2007 | 19 | 0.080 |
Why?
|
Blood | 1 | 1988 | 170 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2011 | 4962 | 0.070 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2007 | 39 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2013 | 930 | 0.070 |
Why?
|
Dogs | 2 | 2020 | 1160 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2007 | 4829 | 0.070 |
Why?
|
Surface Properties | 2 | 1998 | 188 | 0.070 |
Why?
|
Integrin beta1 | 2 | 2005 | 128 | 0.070 |
Why?
|
Antibody Formation | 1 | 2008 | 386 | 0.070 |
Why?
|
Antigens, Viral | 5 | 1993 | 520 | 0.070 |
Why?
|
CD4-CD8 Ratio | 1 | 2007 | 57 | 0.070 |
Why?
|
DNA-Binding Proteins | 5 | 2005 | 5001 | 0.070 |
Why?
|
Olopatadine Hydrochloride | 1 | 2006 | 1 | 0.070 |
Why?
|
Consensus | 2 | 2022 | 1104 | 0.070 |
Why?
|
Fecal Microbiota Transplantation | 2 | 2018 | 168 | 0.070 |
Why?
|
Drug Labeling | 1 | 1987 | 29 | 0.070 |
Why?
|
In Vitro Techniques | 3 | 2007 | 1709 | 0.070 |
Why?
|
Vitreoretinopathy, Proliferative | 1 | 2006 | 6 | 0.070 |
Why?
|
Functional Laterality | 1 | 2008 | 277 | 0.070 |
Why?
|
Rose Bengal | 2 | 1997 | 16 | 0.070 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2006 | 36 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 4 | 2015 | 1901 | 0.070 |
Why?
|
Cadaverine | 1 | 2006 | 7 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2006 | 74 | 0.070 |
Why?
|
Depression, Chemical | 1 | 2006 | 57 | 0.070 |
Why?
|
bcl-2-Associated X Protein | 1 | 2007 | 374 | 0.070 |
Why?
|
Fibrosis | 1 | 2009 | 733 | 0.070 |
Why?
|
Saccharomyces cerevisiae | 1 | 2010 | 662 | 0.070 |
Why?
|
Safety | 2 | 2005 | 461 | 0.070 |
Why?
|
Sirolimus | 2 | 2020 | 831 | 0.070 |
Why?
|
Drug Combinations | 2 | 2000 | 634 | 0.070 |
Why?
|
Risk Factors | 5 | 2017 | 17875 | 0.070 |
Why?
|
Immunoglobulins | 3 | 2019 | 286 | 0.070 |
Why?
|
Species Specificity | 1 | 2007 | 794 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2008 | 374 | 0.070 |
Why?
|
Fibroblasts | 1 | 2012 | 1656 | 0.060 |
Why?
|
Adenoviridae | 2 | 2008 | 1497 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 4491 | 0.060 |
Why?
|
Cataract Extraction | 5 | 1997 | 212 | 0.060 |
Why?
|
HIV Infections | 2 | 1996 | 2154 | 0.060 |
Why?
|
Rabbits | 3 | 1996 | 1028 | 0.060 |
Why?
|
Age Factors | 1 | 2015 | 5464 | 0.060 |
Why?
|
Culture Media | 2 | 1996 | 343 | 0.060 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2005 | 143 | 0.060 |
Why?
|
Bacterial Infections | 4 | 1991 | 508 | 0.060 |
Why?
|
Delphi Technique | 1 | 2006 | 274 | 0.060 |
Why?
|
Infliximab | 1 | 2005 | 138 | 0.060 |
Why?
|
Nanostructures | 2 | 2016 | 101 | 0.060 |
Why?
|
Eye Injuries, Penetrating | 3 | 2000 | 22 | 0.060 |
Why?
|
Suspensions | 1 | 2004 | 18 | 0.060 |
Why?
|
Tonometry, Ocular | 1 | 2004 | 31 | 0.060 |
Why?
|
Necrosis | 4 | 2016 | 595 | 0.060 |
Why?
|
Anti-Infective Agents | 1 | 1989 | 466 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 274 | 0.060 |
Why?
|
Chemokine CCL20 | 2 | 2016 | 39 | 0.060 |
Why?
|
Metalloproteases | 1 | 2004 | 20 | 0.060 |
Why?
|
Disease Progression | 3 | 2017 | 6853 | 0.060 |
Why?
|
Pseudomonas Infections | 3 | 1991 | 166 | 0.060 |
Why?
|
Gene Expression Profiling | 3 | 2012 | 5141 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 1558 | 0.060 |
Why?
|
Incidence | 4 | 2017 | 5821 | 0.060 |
Why?
|
Mechanoreceptors | 1 | 2004 | 29 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 295 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 7017 | 0.060 |
Why?
|
Neurturin | 1 | 2003 | 3 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 2 | 2005 | 1126 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2011 | 1044 | 0.060 |
Why?
|
Etanercept | 1 | 2004 | 68 | 0.060 |
Why?
|
Cathelicidins | 2 | 2014 | 25 | 0.060 |
Why?
|
Mice, Inbred Strains | 1 | 2004 | 563 | 0.060 |
Why?
|
Stromal Cells | 3 | 2014 | 826 | 0.060 |
Why?
|
Matrix Metalloproteinase 11 | 1 | 2003 | 1 | 0.060 |
Why?
|
Matrix Metalloproteinase 10 | 1 | 2003 | 4 | 0.060 |
Why?
|
Cell Cycle | 2 | 2021 | 2137 | 0.060 |
Why?
|
Myeloid Differentiation Factor 88 | 2 | 2016 | 156 | 0.060 |
Why?
|
Cytomegalovirus | 5 | 1995 | 496 | 0.060 |
Why?
|
Genetic Therapy | 2 | 2008 | 1714 | 0.060 |
Why?
|
Retina | 1 | 1987 | 539 | 0.060 |
Why?
|
Child | 9 | 2017 | 30517 | 0.050 |
Why?
|
Comorbidity | 1 | 2010 | 2392 | 0.050 |
Why?
|
Discriminant Analysis | 1 | 2002 | 53 | 0.050 |
Why?
|
Prosthesis Design | 2 | 2018 | 654 | 0.050 |
Why?
|
Cell Nucleus | 2 | 2012 | 1712 | 0.050 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2003 | 189 | 0.050 |
Why?
|
Protein Array Analysis | 1 | 2005 | 503 | 0.050 |
Why?
|
Anesthetics, Local | 2 | 1997 | 179 | 0.050 |
Why?
|
Global Health | 1 | 2008 | 685 | 0.050 |
Why?
|
Child, Preschool | 6 | 2017 | 17028 | 0.050 |
Why?
|
Cathepsins | 1 | 2022 | 56 | 0.050 |
Why?
|
Rats | 2 | 2022 | 6524 | 0.050 |
Why?
|
Coumarins | 1 | 2022 | 38 | 0.050 |
Why?
|
Mice, Inbred CBA | 1 | 2002 | 79 | 0.050 |
Why?
|
Fatty Acids, Volatile | 1 | 2022 | 46 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2003 | 233 | 0.050 |
Why?
|
Health Surveys | 1 | 2003 | 399 | 0.050 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2022 | 44 | 0.050 |
Why?
|
DNA | 1 | 2010 | 3051 | 0.050 |
Why?
|
Eye Banks | 2 | 2018 | 12 | 0.050 |
Why?
|
Fluorometholone | 1 | 2001 | 3 | 0.050 |
Why?
|
Transcription Factor 4 | 2 | 2012 | 33 | 0.050 |
Why?
|
Promoter Regions, Genetic | 1 | 2009 | 3214 | 0.050 |
Why?
|
Amphotericin B | 3 | 2000 | 299 | 0.050 |
Why?
|
Denervation | 1 | 2001 | 35 | 0.050 |
Why?
|
Muscarinic Antagonists | 1 | 2002 | 82 | 0.050 |
Why?
|
Risk Assessment | 1 | 2013 | 6766 | 0.050 |
Why?
|
Colony-Forming Units Assay | 3 | 2006 | 253 | 0.050 |
Why?
|
Antiviral Agents | 2 | 2024 | 1253 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2003 | 322 | 0.050 |
Why?
|
Touch | 1 | 2001 | 70 | 0.050 |
Why?
|
Amnion | 1 | 2001 | 42 | 0.050 |
Why?
|
Hydrogen Peroxide | 1 | 2002 | 223 | 0.050 |
Why?
|
Androgens | 1 | 2004 | 507 | 0.050 |
Why?
|
Poly I-C | 2 | 2011 | 31 | 0.050 |
Why?
|
Autophagosomes | 1 | 2020 | 40 | 0.050 |
Why?
|
Acremonium | 1 | 2000 | 1 | 0.050 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2001 | 51 | 0.050 |
Why?
|
Endothelium, Corneal | 2 | 1992 | 45 | 0.050 |
Why?
|
Collagen | 2 | 1995 | 726 | 0.050 |
Why?
|
Bacterial Capsules | 3 | 2005 | 41 | 0.050 |
Why?
|
Serratia marcescens | 1 | 2000 | 20 | 0.050 |
Why?
|
Tight Junction Proteins | 1 | 2020 | 14 | 0.050 |
Why?
|
Leukocyte Common Antigens | 1 | 2020 | 191 | 0.040 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 62 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2011 | 3438 | 0.040 |
Why?
|
Aminoglycosides | 2 | 1992 | 233 | 0.040 |
Why?
|
Lenses, Intraocular | 5 | 1993 | 394 | 0.040 |
Why?
|
Surgical Flaps | 1 | 2006 | 886 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2000 | 337 | 0.040 |
Why?
|
Aphakia, Postcataract | 2 | 1991 | 20 | 0.040 |
Why?
|
Color | 1 | 1999 | 73 | 0.040 |
Why?
|
Administration, Oral | 2 | 2001 | 1609 | 0.040 |
Why?
|
Lysosomal-Associated Membrane Protein 3 | 1 | 2018 | 2 | 0.040 |
Why?
|
Lung | 1 | 2010 | 3299 | 0.040 |
Why?
|
Protein Transport | 2 | 2012 | 737 | 0.040 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2018 | 16 | 0.040 |
Why?
|
Mice, Inbred MRL lpr | 1 | 1998 | 26 | 0.040 |
Why?
|
Drug Carriers | 1 | 2020 | 337 | 0.040 |
Why?
|
Chemokine CXCL1 | 1 | 2018 | 67 | 0.040 |
Why?
|
Hyperplasia | 1 | 2000 | 565 | 0.040 |
Why?
|
Beclin-1 | 1 | 2018 | 88 | 0.040 |
Why?
|
Infant | 4 | 2017 | 13982 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2020 | 272 | 0.040 |
Why?
|
United States | 2 | 2014 | 15834 | 0.040 |
Why?
|
Autonomic Nervous System | 1 | 1998 | 74 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 1642 | 0.040 |
Why?
|
Surgical Wound Infection | 2 | 1993 | 480 | 0.040 |
Why?
|
DNA Damage | 2 | 2017 | 1988 | 0.040 |
Why?
|
Quinazolines | 2 | 2013 | 956 | 0.040 |
Why?
|
Proteins | 2 | 1996 | 2043 | 0.040 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 1998 | 86 | 0.040 |
Why?
|
Herpesvirus 3, Human | 2 | 1995 | 45 | 0.040 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2018 | 168 | 0.040 |
Why?
|
Acute Disease | 3 | 2018 | 2495 | 0.040 |
Why?
|
Cell Lineage | 1 | 2020 | 701 | 0.040 |
Why?
|
Lidocaine | 1 | 1997 | 82 | 0.040 |
Why?
|
Tissue Distribution | 2 | 2010 | 929 | 0.040 |
Why?
|
Mitosporic Fungi | 1 | 1997 | 19 | 0.040 |
Why?
|
Gene Amplification | 2 | 1990 | 766 | 0.040 |
Why?
|
Retinal Detachment | 2 | 1988 | 86 | 0.040 |
Why?
|
Nasal Mucosa | 1 | 1997 | 84 | 0.040 |
Why?
|
Aerosols | 1 | 1997 | 150 | 0.040 |
Why?
|
Deubiquitinating Enzymes | 1 | 2017 | 35 | 0.040 |
Why?
|
Ligands | 2 | 2010 | 1016 | 0.040 |
Why?
|
S Phase | 1 | 1998 | 288 | 0.040 |
Why?
|
Oligonucleotide Probes | 2 | 1994 | 154 | 0.040 |
Why?
|
Light | 1 | 2018 | 279 | 0.030 |
Why?
|
Drug Resistance, Microbial | 3 | 1992 | 243 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2004 | 3242 | 0.030 |
Why?
|
Mink | 1 | 1996 | 9 | 0.030 |
Why?
|
Bacteria | 5 | 2003 | 653 | 0.030 |
Why?
|
Cellular Senescence | 1 | 2019 | 389 | 0.030 |
Why?
|
Cholinergic Agents | 1 | 1996 | 21 | 0.030 |
Why?
|
Cystine | 1 | 2016 | 33 | 0.030 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2017 | 109 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2023 | 1585 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 1996 | 229 | 0.030 |
Why?
|
Propionibacterium acnes | 2 | 1993 | 24 | 0.030 |
Why?
|
Capnocytophaga | 2 | 1993 | 4 | 0.030 |
Why?
|
Disease Transmission, Infectious | 1 | 1997 | 99 | 0.030 |
Why?
|
Integrin alpha4 | 1 | 2015 | 26 | 0.030 |
Why?
|
Neutrophil Infiltration | 1 | 2016 | 108 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2022 | 3043 | 0.030 |
Why?
|
Lymph Nodes | 3 | 2013 | 3078 | 0.030 |
Why?
|
Random Allocation | 1 | 1997 | 741 | 0.030 |
Why?
|
Culture Techniques | 1 | 1995 | 146 | 0.030 |
Why?
|
Integrin alpha4beta1 | 1 | 2015 | 46 | 0.030 |
Why?
|
Oxygenases | 1 | 2015 | 26 | 0.030 |
Why?
|
B-Lymphocytes | 2 | 2012 | 1424 | 0.030 |
Why?
|
Acetylcysteine | 1 | 1996 | 136 | 0.030 |
Why?
|
Triamcinolone | 1 | 1995 | 25 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 1996 | 296 | 0.030 |
Why?
|
Stilbenes | 1 | 2016 | 86 | 0.030 |
Why?
|
Histocytochemistry | 1 | 1995 | 198 | 0.030 |
Why?
|
Drug Liberation | 1 | 2015 | 19 | 0.030 |
Why?
|
Epidermis | 1 | 2016 | 196 | 0.030 |
Why?
|
Sex Characteristics | 1 | 1998 | 426 | 0.030 |
Why?
|
Cytomegalovirus Retinitis | 1 | 1995 | 16 | 0.030 |
Why?
|
Toxoplasma | 1 | 1995 | 14 | 0.030 |
Why?
|
Vitamin B Complex | 1 | 2015 | 52 | 0.030 |
Why?
|
Laminin | 1 | 1995 | 209 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 124 | 0.030 |
Why?
|
Diffusion | 1 | 2015 | 95 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 11 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 1996 | 154 | 0.030 |
Why?
|
NIH 3T3 Cells | 2 | 2005 | 255 | 0.030 |
Why?
|
Antigens, Ly | 1 | 2014 | 51 | 0.030 |
Why?
|
Proteoglycans | 1 | 1995 | 278 | 0.030 |
Why?
|
Lectins, C-Type | 1 | 2015 | 163 | 0.030 |
Why?
|
Lipid Peroxidation | 1 | 2015 | 164 | 0.030 |
Why?
|
Axons | 1 | 2018 | 441 | 0.030 |
Why?
|
Galectin 3 | 1 | 2015 | 131 | 0.030 |
Why?
|
Adenoviruses, Human | 1 | 1995 | 191 | 0.030 |
Why?
|
Alkylating Agents | 1 | 2014 | 81 | 0.030 |
Why?
|
Morphogenesis | 1 | 1995 | 319 | 0.030 |
Why?
|
Hepatitis B | 1 | 1997 | 274 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 704 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2017 | 622 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 3 | 1990 | 250 | 0.030 |
Why?
|
Herpes Simplex | 1 | 1995 | 100 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2016 | 722 | 0.030 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 2 | 1990 | 53 | 0.030 |
Why?
|
Spectrum Analysis, Raman | 1 | 2013 | 38 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 1991 | 368 | 0.030 |
Why?
|
CD11c Antigen | 1 | 2013 | 56 | 0.030 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 1993 | 76 | 0.030 |
Why?
|
Leukocytes | 1 | 2015 | 422 | 0.030 |
Why?
|
Toll-Like Receptor 5 | 1 | 2013 | 11 | 0.030 |
Why?
|
Receptor, Muscarinic M3 | 1 | 2012 | 21 | 0.030 |
Why?
|
Cadaver | 1 | 1993 | 202 | 0.030 |
Why?
|
Indazoles | 1 | 2015 | 310 | 0.030 |
Why?
|
Receptors, Interleukin | 1 | 2013 | 99 | 0.030 |
Why?
|
Autocrine Communication | 1 | 2013 | 88 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 2013 | 95 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2012 | 111 | 0.030 |
Why?
|
Mice, 129 Strain | 1 | 2012 | 160 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2013 | 316 | 0.030 |
Why?
|
Transcription Factor RelA | 1 | 2013 | 184 | 0.030 |
Why?
|
Tobramycin | 1 | 1992 | 25 | 0.030 |
Why?
|
Streptococcus | 1 | 1992 | 79 | 0.030 |
Why?
|
Gram-Negative Bacteria | 1 | 1992 | 106 | 0.020 |
Why?
|
3T3 Cells | 1 | 2012 | 383 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2013 | 325 | 0.020 |
Why?
|
Ambrosia | 1 | 2011 | 14 | 0.020 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1993 | 163 | 0.020 |
Why?
|
Diglycerides | 1 | 2011 | 35 | 0.020 |
Why?
|
Cooking and Eating Utensils | 1 | 1991 | 3 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 1993 | 1050 | 0.020 |
Why?
|
Culture Media, Serum-Free | 1 | 2011 | 80 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 2650 | 0.020 |
Why?
|
Sulfamethoxazole | 1 | 1990 | 4 | 0.020 |
Why?
|
Trimethoprim | 1 | 1990 | 7 | 0.020 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 1 | 1990 | 47 | 0.020 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 2 | 2001 | 40 | 0.020 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 1990 | 67 | 0.020 |
Why?
|
Receptors, Interleukin-17 | 1 | 2010 | 26 | 0.020 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1990 | 88 | 0.020 |
Why?
|
Acyclovir | 1 | 1990 | 79 | 0.020 |
Why?
|
Herpesviridae | 1 | 1991 | 43 | 0.020 |
Why?
|
Rubella virus | 1 | 1990 | 10 | 0.020 |
Why?
|
Drug Contamination | 1 | 1990 | 51 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2012 | 1054 | 0.020 |
Why?
|
Gentamicins | 2 | 1988 | 111 | 0.020 |
Why?
|
Sialic Acid Binding Ig-like Lectin 2 | 1 | 1990 | 59 | 0.020 |
Why?
|
Skin | 1 | 2016 | 1273 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 170 | 0.020 |
Why?
|
Tuberculosis, Ocular | 1 | 1989 | 4 | 0.020 |
Why?
|
Osmosis | 1 | 2010 | 20 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2013 | 476 | 0.020 |
Why?
|
I-kappa B Kinase | 1 | 2011 | 248 | 0.020 |
Why?
|
Tumor Necrosis Factors | 1 | 2010 | 34 | 0.020 |
Why?
|
Cytoskeletal Proteins | 1 | 1992 | 522 | 0.020 |
Why?
|
DNA Probes | 1 | 2010 | 247 | 0.020 |
Why?
|
Receptors, OX40 | 1 | 2010 | 51 | 0.020 |
Why?
|
Receptors, Complement | 1 | 1990 | 48 | 0.020 |
Why?
|
Pollen | 1 | 2010 | 46 | 0.020 |
Why?
|
Antigens | 1 | 1990 | 281 | 0.020 |
Why?
|
CD3 Complex | 1 | 1990 | 320 | 0.020 |
Why?
|
Gene Deletion | 1 | 2014 | 1473 | 0.020 |
Why?
|
Receptors, Virus | 1 | 1990 | 153 | 0.020 |
Why?
|
Immune System Phenomena | 1 | 2009 | 4 | 0.020 |
Why?
|
Miconazole | 1 | 1989 | 6 | 0.020 |
Why?
|
Plant Proteins | 1 | 2010 | 133 | 0.020 |
Why?
|
Gene Silencing | 1 | 2012 | 827 | 0.020 |
Why?
|
Patient Compliance | 1 | 2013 | 678 | 0.020 |
Why?
|
Infarction | 1 | 1989 | 35 | 0.020 |
Why?
|
Anesthetics | 1 | 1990 | 118 | 0.020 |
Why?
|
Oligopeptides | 1 | 2011 | 447 | 0.020 |
Why?
|
Tissue Donors | 2 | 1997 | 815 | 0.020 |
Why?
|
Protein Binding | 1 | 2015 | 3485 | 0.020 |
Why?
|
Lymphogranuloma Venereum | 1 | 1988 | 2 | 0.020 |
Why?
|
Calibration | 1 | 1989 | 347 | 0.020 |
Why?
|
Interleukin-7 | 1 | 2009 | 92 | 0.020 |
Why?
|
Staphylococcus epidermidis | 1 | 1988 | 66 | 0.020 |
Why?
|
Benzamidines | 1 | 2008 | 13 | 0.020 |
Why?
|
Retinal Vessels | 1 | 1989 | 82 | 0.020 |
Why?
|
Methods | 1 | 1988 | 223 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2010 | 848 | 0.020 |
Why?
|
Nitriles | 1 | 2013 | 938 | 0.020 |
Why?
|
Vision, Binocular | 1 | 2008 | 45 | 0.020 |
Why?
|
Antiprotozoal Agents | 1 | 2008 | 42 | 0.020 |
Why?
|
Allergens | 1 | 2010 | 252 | 0.020 |
Why?
|
Quinolines | 1 | 2011 | 403 | 0.020 |
Why?
|
Electroretinography | 1 | 1988 | 126 | 0.020 |
Why?
|
Substance-Related Disorders | 2 | 1990 | 547 | 0.020 |
Why?
|
Suction | 1 | 1988 | 121 | 0.020 |
Why?
|
Pigment Epithelium of Eye | 1 | 1987 | 40 | 0.020 |
Why?
|
Sensory Aids | 1 | 1987 | 1 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 1990 | 1312 | 0.020 |
Why?
|
Thymus Gland | 1 | 2009 | 311 | 0.020 |
Why?
|
Eye Enucleation | 3 | 1993 | 87 | 0.020 |
Why?
|
Panophthalmitis | 1 | 1987 | 2 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2010 | 1069 | 0.020 |
Why?
|
Bacillus cereus | 1 | 1987 | 12 | 0.020 |
Why?
|
Vision, Ocular | 1 | 1988 | 135 | 0.020 |
Why?
|
Cellulitis | 1 | 1987 | 79 | 0.020 |
Why?
|
Parotid Gland | 1 | 1986 | 116 | 0.020 |
Why?
|
Reading | 1 | 1987 | 87 | 0.020 |
Why?
|
Salivary Glands | 1 | 1986 | 139 | 0.020 |
Why?
|
Biotin | 1 | 2006 | 78 | 0.020 |
Why?
|
Cross Infection | 1 | 1991 | 546 | 0.020 |
Why?
|
Equipment Design | 1 | 1989 | 1207 | 0.020 |
Why?
|
Spleen | 1 | 2008 | 726 | 0.020 |
Why?
|
Texas | 1 | 2017 | 6436 | 0.020 |
Why?
|
Orbital Diseases | 1 | 1987 | 123 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2005 | 432 | 0.020 |
Why?
|
Interferon-alpha | 1 | 1990 | 959 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 1997 | 9039 | 0.020 |
Why?
|
Florida | 2 | 1998 | 116 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2005 | 452 | 0.020 |
Why?
|
Smad2 Protein | 1 | 2005 | 89 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 1989 | 488 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 1095 | 0.020 |
Why?
|
Gene Targeting | 1 | 2006 | 314 | 0.020 |
Why?
|
Intraocular Pressure | 1 | 2005 | 156 | 0.020 |
Why?
|
Calcium | 1 | 2011 | 1588 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1990 | 1135 | 0.010 |
Why?
|
Receptors, Transferrin | 1 | 2004 | 40 | 0.010 |
Why?
|
Nestin | 1 | 2004 | 42 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2474 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2006 | 417 | 0.010 |
Why?
|
Genes, erbB-1 | 1 | 2004 | 104 | 0.010 |
Why?
|
Drug Synergism | 1 | 1987 | 1359 | 0.010 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2004 | 88 | 0.010 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2004 | 239 | 0.010 |
Why?
|
Clone Cells | 1 | 2005 | 591 | 0.010 |
Why?
|
Bacteriological Techniques | 1 | 2003 | 123 | 0.010 |
Why?
|
Integrins | 1 | 2004 | 275 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 4774 | 0.010 |
Why?
|
Ribonucleases | 1 | 2001 | 96 | 0.010 |
Why?
|
Receptors, Interleukin-1 | 1 | 2001 | 97 | 0.010 |
Why?
|
Cadherins | 1 | 2004 | 657 | 0.010 |
Why?
|
Eye Foreign Bodies | 1 | 2000 | 16 | 0.010 |
Why?
|
Blotting, Southern | 2 | 1990 | 453 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 4960 | 0.010 |
Why?
|
Nontuberculous Mycobacteria | 1 | 1998 | 49 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2000 | 311 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1996 | 10383 | 0.010 |
Why?
|
Hepatitis B Core Antigens | 1 | 1997 | 28 | 0.010 |
Why?
|
Hepatitis B Antibodies | 1 | 1997 | 56 | 0.010 |
Why?
|
Hepatitis B Surface Antigens | 1 | 1997 | 89 | 0.010 |
Why?
|
Serologic Tests | 1 | 1997 | 147 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 1582 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 1997 | 359 | 0.010 |
Why?
|
Fungi | 1 | 1996 | 147 | 0.010 |
Why?
|
Hepatitis B virus | 1 | 1997 | 225 | 0.010 |
Why?
|
Algorithms | 1 | 2006 | 3900 | 0.010 |
Why?
|
Biomarkers, Tumor | 2 | 2005 | 10701 | 0.010 |
Why?
|
Injections | 1 | 1995 | 286 | 0.010 |
Why?
|
Erythromycin | 1 | 1993 | 23 | 0.010 |
Why?
|
Prednisone | 1 | 1996 | 1032 | 0.010 |
Why?
|
Chlamydia Infections | 1 | 1993 | 48 | 0.010 |
Why?
|
Virus Cultivation | 1 | 1992 | 80 | 0.010 |
Why?
|
Lymphoid Tissue | 1 | 1992 | 102 | 0.010 |
Why?
|
Herpes Zoster | 1 | 1992 | 53 | 0.010 |
Why?
|
Cephalosporins | 1 | 1993 | 174 | 0.010 |
Why?
|
Tissue Adhesives | 1 | 1992 | 47 | 0.010 |
Why?
|
Propionibacterium | 1 | 1991 | 4 | 0.010 |
Why?
|
Corynebacterium Infections | 1 | 1991 | 8 | 0.010 |
Why?
|
Trabeculectomy | 1 | 1991 | 17 | 0.010 |
Why?
|
Autoradiography | 1 | 1991 | 154 | 0.010 |
Why?
|
Retinitis | 1 | 1991 | 19 | 0.010 |
Why?
|
Facial Paralysis | 1 | 1991 | 57 | 0.010 |
Why?
|
Flucytosine | 1 | 1990 | 33 | 0.010 |
Why?
|
Ketoconazole | 1 | 1990 | 36 | 0.010 |
Why?
|
Disinfection | 1 | 1990 | 38 | 0.010 |
Why?
|
Equipment Contamination | 1 | 1991 | 85 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 1990 | 159 | 0.010 |
Why?
|
Receptors, Complement 3d | 1 | 1990 | 9 | 0.010 |
Why?
|
Cross Reactions | 1 | 1990 | 263 | 0.010 |
Why?
|
Glaucoma | 1 | 1991 | 101 | 0.010 |
Why?
|
Disposable Equipment | 1 | 1989 | 22 | 0.010 |
Why?
|
Drug Administration Routes | 1 | 1989 | 61 | 0.010 |
Why?
|
Solutions | 1 | 1989 | 108 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 1990 | 632 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 1989 | 148 | 0.010 |
Why?
|
Methicillin | 1 | 1988 | 46 | 0.010 |
Why?
|
Cefazolin | 1 | 1988 | 27 | 0.000 |
Why?
|
Candida | 1 | 1990 | 171 | 0.000 |
Why?
|
Chlamydia trachomatis | 1 | 1988 | 29 | 0.000 |
Why?
|
Solvents | 1 | 1988 | 66 | 0.000 |
Why?
|
Reoperation | 1 | 1993 | 1391 | 0.000 |
Why?
|
Cytomegalovirus Infections | 1 | 1991 | 494 | 0.000 |
Why?
|
Wounds, Nonpenetrating | 1 | 1988 | 224 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 1988 | 1416 | 0.000 |
Why?
|